Highlights
- Market Cap
- $2.12B
- Enterprise Value
- $2.28B
- EPS (TTM)
- -$0.32
- Total Revenue (TTM)
- $330.51M
- Gross Profit (TTM)
- $274.90M
- EBITDA (TTM)
- -$25.65M
- Year Range
- $9.20 - $15.73
- ROA (TTM)
- -4.59%
- ROE (TTM)
- -8.13%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Dynavax Technologies Corporation, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Dynavax Technologies Corporation
- 1D
- —
- 1M
- —
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.68% | 0.10% | 0.78% | ||||||||||
| 2025 | 2.19% | 5.67% | -5.95% | -9.41% | -16.68% | 1.33% | 10.69% | -7.83% | -1.88% | 3.32% | 10.82% | 35.27% | 20.44% |
| 2024 | -7.58% | -1.93% | -2.05% | -8.38% | 5.45% | -6.34% | -0.36% | 0.27% | -0.71% | 6.37% | 8.52% | -0.70% | -8.66% |
| 2023 | 6.95% | -9.49% | -4.76% | 6.12% | 9.80% | 13.04% | 8.28% | 2.64% | 2.86% | -3.79% | -3.59% | 2.04% | 31.39% |
| 2022 | -7.82% | -5.47% | -11.58% | -18.54% | 34.31% | 6.16% | 14.22% | -20.24% | -8.98% | 9.67% | 8.38% | -14.26% | -24.38% |
| 2021 | 41.80% | 38.67% | 12.34% | 1.53% | -17.84% | 20.12% | -5.18% | 108.35% | -1.28% | 3.96% | -19.13% | -12.88% | 216.18% |
Benchmark Metrics
Dynavax Technologies Corporation has an annualized alpha of 36.84%, beta of 0.90, and R² of 0.02 versus S&P 500 Index. Calculated based on daily prices since February 20, 2004.
- This stock participated in 195.05% of S&P 500 Index downside but only 155.02% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.02 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 36.84%
- Beta
- 0.90
- R²
- 0.02
- Upside Capture
- 155.02%
- Downside Capture
- 195.05%
Return for Risk
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Dynavax Technologies Corporation (DVAX) and compare them to a chosen benchmark (S&P 500 Index).
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Dynavax Technologies Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Dynavax Technologies Corporation was 98.47%, occurring on Nov 20, 2008. The portfolio has not yet recovered.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -98.47% | Dec 12, 2006 | 490 | Nov 20, 2008 | — | — | — |
| -61.81% | Feb 20, 2004 | 291 | Apr 15, 2005 | 410 | Nov 29, 2006 | 701 |
| -7.25% | Nov 30, 2006 | 2 | Dec 1, 2006 | 6 | Dec 11, 2006 | 8 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Dynavax Technologies Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Dynavax Technologies Corporation is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for DVAX relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, DVAX has a P/S ratio of 6.4. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for DVAX in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, DVAX has a P/B value of 4.0. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |